Licensing Down in H1 2023 as Dealmakers Remain Cautious

Amid the challenging macroeconomic climate, licensing deals have emerged as a preferred alternative to M&A for some big pharma, as they allow companies to gain access to new technologies and modalities in risk mitigated and financially back-loaded deal structures.

In line with the overall decline in dealmaking activity, licensing deal flow for life science companies declined in H1 2023 relative to H1 2022, as licensees became more selective in the types of assets they wished to invest in. However, despite aggregate deal spend decreasing, average upfront payments rose in H1 2023, thanks in part to an increase in the number of deals centered on later stage assets and escalating asset valuations.

To learn about the latest lcensing pharma deal activity, please download the article.

Business Intelligence

Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.

Brand Strategy and Management

Be proactive about growing your brand using the latest in data, analytics, and domain expertise.

Commercialization

Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.

To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Related solutions